

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 213/79, C07C 237/26, A61K 31/44, 31/65		A1	(11) International Publication Number: WO 95/22529
			(43) International Publication Date: 24 August 1995 (24.08.95)
(21) International Application Number: PCT/IB95/00026		(81) Designated States: AU, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 12 January 1995 (12.01.95)			
(30) Priority Data: 08/198,801 17 February 1994 (17.02.94) US		Published With international search report.	
(60) Parent Application or Grant (63) Related by Continuation US 08/198,801 (CIP) Filed on 17 February 1994 (17.02.94)			
(71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): SU, Wei-guo [CN/US]; 182 Gales Ferry Road, Groton, CT 06340 (US).			
(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).			

(54) Title: 9-(SUBSTITUTED AMINO)-ALPHA-6-DEOXY-5-OXY TETRACYCLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS



(57) Abstract

This invention relates to compounds of formula (I) wherein R¹ is hydrogen or -CH₂NR⁵R⁶; R² is hydrogen or R⁴(CH₂)_nCO-; n is an integer from 0 to 4; R³ is R⁸(CH₂)_mCO- or R⁸(CH₂)_mSO₂-; m is an integer from 0 to 4; R⁴, R⁵, R⁶ and R⁸ are defined as in the specification and the pharmaceutically acceptable salts of such compounds. Compounds of formula (I) exhibit antibiotic activity against a wide range of gram-positive and gram-negative organisms, including organisms that are resistant to tetracycline antibiotics.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics

This invention relates to novel doxycycline analogs that exhibit antibiotic activity against a wide range of gram-positive and gram-negative organisms, including organisms that are resistant to tetracycline antibiotics.

Doxycycline (α -6-deoxy-5-oxytetracycline) and other 6-deoxytetracyclines are referred to in articles by Stephens *et al.*, *J. Amer. Chem. Soc.*, **85**, 2643-2652 (Sept. 5, 1963) and Petisi *et al.*, *J. Med. Pharm. Chem.*, **5** 538 (1962). They are also referred to in United States Patent 3,200,149, which issued on August 10, 1965.


European Patent Application 536515A1, which was published on April 14, 1993, refers to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds that exhibit activity against a wide spectrum of organisms including organisms that are resistant to tetracyclines. This application and the foregoing references are incorporated herein by reference in their entireties.

Summary of the Invention

This invention relates to compounds of the formula

20

25



wherein R^1 is hydrogen or $-\text{CH}_2\text{NR}^5\text{R}^6$;

R^2 is hydrogen or $\text{R}^4(\text{CH}_2)_n\text{CO}-$;

30

n is an integer from 0 to 4;

R^3 is $\text{R}^8(\text{CH}_2)_m\text{CO}-$ or $\text{R}^8(\text{CH}_2)_m\text{SO}_2-$;

m is an integer from 0 to 4;

and when n is 0, then either:


(a) R^4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C_1 - C_6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino and phenylamino; disubstituted amino selected from dimethylamino, diethylamino, thyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl,

-2-

morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) and 4-(1,2,4-triazolyl); straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl; (C₃-C₆)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; substituted (C₃-C₆)cycloalkyl
 5 (substitution selected from (C₁-C₃)alkyl, cyano, amino and (C₁-C₃)acyl); (C₆-C₁₀)aryl selected from phenyl, α -naphthyl and β -naphthyl; substituted (C₆-C₁₀)aryl (substitution selected from halo, (C₁-C₄)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl, (C₁-C₃)alkylamino and carboxy); (C₇-C₉)aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl and phenylpropyl; α -amino-(C₁-C₄)alkyl selected from
 10 aminomethyl, α -aminoethyl, α -aminopropyl and α -aminobutyl; carboxy(C₂-C₄)-alkylamino selected from aminoacetic acid, α -aminobutyric acid and α -aminopropionic acid and their optical isomers; (C₇-C₉)aralkylamino (e.g., phenylglycyl); (C₁-C₄)alkoxycarbonylamino substituted (C₁-C₄)alkyl, substitution selected from phenyl and p-hydroxyphenyl; α -hydroxy(C₁-C₃)alkyl selected from hydroxymethyl, α -hydroxyethyl, α -hydroxy-1-methylethyl and α -hydroxypropyl; α -mercaptopropyl; and halo-(C₁-C₃)alkyl;
 15 or

(b) R⁴ is selected from Q¹, Q² and Q³, wherein Q¹ is a five membered aromatic or saturated ring containing one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto (e.g.,


20



25 wherein Z is N, O, S or Se);

Q² is a five membered aromatic ring containing two heteroatoms independently selected from N, O, S and Se and optionally having a benzo or pyrido ring fused thereto (e.g.,


30



wherein Z and Z¹ are independently selected from N, O, S and S); and

-3-

Q³ is a five membered saturated ring containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom (for example,



10 wherein A is selected from hydrogen; straight or branched (C₁-C₄)alkyl; C₆-aryl; substituted C₆-aryl (substitution selection from halo, (C₁-C₄)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl, (C₁-C₃)alkylamino and carboxy); (C₇-C₉)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl and phenylpropyl); or

15 (c) R⁴ is a six membered aromatic ring containing from one to three heteroatoms independently selected from N, O, S and Se (e.g., pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C₁-C₃)alkylthiopyridazinyl), or a six membered saturated ring containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom (e.g., 2,3-dioxo-1-
20 piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholino and 2-dioxothiomorpholino); or

(d) R⁴ is selected from acetyl, propionyl; chloroacetyl; trifluoroacetyl; (C₃-C₆)cycloalkylcarbonyl (e.g., cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,2-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopropyl)carbonyl or (3-ethylcyclobutyl)carbonyl); (C₁-C₁₀)aroyl selected from benzoyl and naphthoyl; halo substituted (C₆-C₁₀)aroyl (e.g., pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl); (C₁-C₄)alkylbenzoyl; and (heterocycle)carbonyl, wherein said heterocycle is selected from the group consisting of Q¹, Q², Q³, six
25 membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and S and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; or
30

-4-

(e) R^4 is selected from (C_1-C_4) alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl and allyloxycarbonyl; vinyl; and substituted vinyl [substitution selected from (C_1-C_3) alkyl, halo, (C_6-C_{10}) aryl selected from phenyl, α -naphthyl and β -naphthyl, substituted (C_6-C_{10}) aryl (substitution selected from halo, (C_1-C_4) alkoxy, trihalo (C_1-C_3) alkyl, nitro, amino, cyano, (C_1-C_4) alkoxycarbonyl, (C_1-C_3) alkylamino and carboxy), halo (C_1-C_3) alkyl, and Q^1 , wherein Q^1 is defined as above]; or

(f) R^4 is selected from (C_1-C_4) alkoxy; C_6 -aryloxy selected from phenoxy and substituted phenoxy (substitution selected from halo, (C_1-C_4) alkyl, nitro, cyano, thiol, amino, carboxy and di (C_1-C_3) alkylamino); (C_7-C_{10}) aralkyloxy (e.g., benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy); vinyloxy and substituted vinyloxy (substitution selected from (C_1-C_4) alkyl, cyano, carboxy, and (C_6-C_{10}) aryl selected from phenyl, α -naphthyl and β -naphthyl); R^aR^b amino (C_1-C_4) alkoxy, wherein R^aR^b is straight or branched (C_1-C_4) alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is $(CH_2)_p$ wherein p is 2-6, or R^aR^b is $-(CH_2)_2W(CH_2)_2-$ wherein W is selected from -N (C_1-C_3) alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C_1-C_3) alkyl), O and S; and R^aR^b aminoxy, wherein R^aR^b is a straight or branched (C_1-C_4) alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl, or R^aR^b is $(CH_2)_p$ wherein p is 2-6, or R^aR^b is $-(CH_2)_2W(CH_2)_2-$ wherein W is selected from -N (C_1-C_3) alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C_1-C_3) alkyl), O and S;

and when n is 1, 2, 3 or 4, then either:

(a) R^4 is selected from hydrogen; amino; straight or branched (C_1-C_4) alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl; (C_3-C_6) cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; substituted (C_3-C_6) cycloalkyl group (substitution selected from (C_1-C_3) alkyl, cyano, amino and (C_1-C_3) acyl); (C_6-C_{10}) aryl selected from phenyl, α -naphthyl and β -naphthyl; substituted (C_6-C_{10}) aryl (substitution selected from halo, (C_1-C_4) alkoxy, trihalo (C_1-C_3) alkyl, nitro, amino, cyano, (C_1-C_4) alkoxycarbonyl, (C_1-C_3) alkylamino and carboxy); (C_7-C_9) aralkyl (e.g., benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl); acetyl; propionyl; chloroacetyl; trichloroacetyl; (C_6-C_{10}) aroyl selected from benzoyl and naphthoyl; halo substituted (C_6-C_{10}) aroyl (e.g., pentafluorobenzoyl,

-5-

4-chlorobenzoyl, 3-bromobenzoyl and 3,4-difluorobenzoyl); (C₁-C₄)alkylbenzoyl (e.g., 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl); (C₃-C₆)cycloalkylcarbonyl; and (heterocycle)carbonyl, wherein the heterocycle moiety is selected from the group consisting of Q¹, Q², Q³, six membered aromatic rings containing from one to three
5 heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; or

(b) R⁴ is selected from (C₁-C₄)alkoxy; C₆-aryloxy selected from phenoxy and
10 substituted phenoxy (substitution selected from halo, (C₁-C₄)alkyl, nitro, cyano, thiol, amino, carboxy and di(C₁-C₃)alkylamino); (C₇-C₁₀)aralkyloxy (e.g., benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy); (C₁-C₃)alkylthio selected from methylthio, ethylthio, propylthio and allylthio; C₆-arylthio selected from phenylthio and substituted phenylthio (substitution selected from halo, (C₁-C₄)alkyl, nitro, cyano, thiol, amino, carboxy and
15 di(C₁-C₃)alkylamino); C₆-arylsulfonyl selected from phenylsulfonyl and substituted phenylsulfonyl (substitution selected from halo, (C₁-C₄)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl, (C₁-C₃)alkylamino and carboxy); and (C₇-C₈)aralkylthio (e.g., benzylthio, 1-phenylethylthio or 2-phenylethylthio); or

(c) R⁴ is selected from Q¹, Q², Q³, six membered aromatic rings containing
20 from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; or

(d) R⁴ is selected from hydroxy; mercapto; mono- or di-straight or branched
25 chain (C₁-C₆)alkylamino selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl and 1-methyl-1-ethylpropyl amino; (C₂-C₆)azacycloalkyl (e.g., aziridinyl, azetidiny, pyrrolidinyl,
30 piperidinyl, morpholino or 2-methylpyrrolidinyl); carboxy(C₂-C₄)alkylamino selected from aminoacetic acid, α -aminopropionic acid, α -aminobutyric acid and their optical isomers; α -hydroxy(C₁-C₃)alkyl selected from hydroxymethyl, α -hydroxyethyl, α -hydroxy-1-methylethyl and α -hydroxypropyl; halo(C₁-C₃) alkyl; acetyl; propionyl; chloroacetyl;

-6-

trifluoroacetyl; (C₆-C₁₀)aroyl selected from benzoyl and naphthoyl; halo substituted (C₆-C₁₀)aroyl (e.g., pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl, or 3,4-difluorobenzoyl); (C₁-C₄)alkylbenzoyl; (e.g., 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl); (C₃-C₆)cycloalkylcarbonyl; and (heterocycle)carbonyl, wherein the
 5 heterocycle moiety is selected from Q¹, Q², Q³, six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; or

10 (e) R⁴ is selected from (C₁-C₄)alkoxycarbonylamino selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino and propoxycarbonylamino; (C₁-C₄)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, and straight or branched butoxycarbonyl; allyloxycarbonyl; R^aR^bamino(C₁-C₄)alkoxy, wherein R^aR^b
 15 is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂- wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S; and R^aR^baminooxy, wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl,
 20 ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂- wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S;

and when R³ is R^j(CH₂)_mCO and m is 0, then R⁸ is independently selected from
 25 the same group of substituents that R⁴ is selected from when n is 0;

and when R³ is R⁸(CH₂)_mCO and m is 1, 2, 3 or 4, then R₈ is independently selected from the same group of substituents that R⁴ is selected from when n is 1, 2, 3 or 4;

and when R³ is R⁸(CH₂)_mSO₂ and m is 0, then either:

30 (a) R⁸ is selected from amino; monosubstituted amino selected from straight or branched (C₁-C₆)-alkylamino, cyclopylamino, cyclobutylamino, benzylamino and phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morphollnyl, 1-imidazolyl, 1-

-7-

- pyrrolyl, 1-(1,2,3-triazolyl) and 4-(1,2,4-triazolyl); straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl; (C₃-C₆)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; substituted (C₃-C₆)cycloalkyl (substitution selected from (C₁-C₃)alkyl, cyano, amino and (C₁-C₃)acyl); (C₆-C₁₀)aryl selected from phenyl, α -naphthyl and β -naphthyl; substituted (C₆-C₁₀)aryl (substitution selected from halo, (C₁-C₄)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl, (C₁-C₃)alkylamino and carboxy); (C₇-C₉)aralkyl (e.g., benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl); and halo(C₁-C₃)alkyl; or
- 5 (b) R^b is a heterocycle group selected from Q¹, Q², Q³, six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; R^aR^bamino(C₁-C₄)alkoxy, wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W-(CH₂)₂-, wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S; and R^aR^b aminoxy, wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂- wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen or (C₁-C₃)alkyl), O and S, wherein Q¹, Q² and Q³ are defined as above;
- 15 and when R³ is R^b (CH₂)_mSO₂ and m is 1, 2, 3, or 4, then either:
- 25 (a) R^b is selected from hydrogen; straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl; (C₁-C₄)carboxyalkyl; (C₃-C₆)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; substituted (C₃-C₆)cycloalkyl (substitution selected from (C₁-C₃)alkyl, cyano, amino and (C₁-C₃)acyl); (C₆-C₁₀)aryl selected from phenyl, α -naphthyl and β -naphthyl; substituted (C₆-C₁₀)aryl (substitution selected from halo, (C₁-C₃)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl, (C₁-C₃)alkylamino and carboxy); (C₇-C₉)aralkyl (e.g., benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl); (C₁-C₄)alkoxy; C₆-aryloxy selected from phenoxy and substituted
- 30

-8-

phenoxy (substitution selected from halo, (C₁-C₃)alkyl, nitro, cyano, thiol, amino, carboxy and di(C₁-C₃)alkylamino); (C₇-C₁₀)aralkyloxy (e.g., benzyloxy, 1-phenylethoxy or 2-phenylethoxy); R^aR^bamino(C₁-C₄)alkoxy, wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂-, wherein W selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S; and R^aR^b aminoxy; wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂-, wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S; or

(b) R⁸ is selected from (C₁-C₃)alkylthio selected from methylthio, ethylthio and n-propylthio; C₆-arylthio selected from phenylthio and substituted phenylthio (substitution selected from halo, (C₁-C₃)alkyl, nitro, cyano, thiol, amino, carboxy and di(C₁-C₃)alkylamino); (C₇-C₈)aralkylthio (e.g., benzylthio, 1-phenylethylthio or 2-phenylethylthio); and heterocycle groups selected from the group consisting of Q¹, Q², Q³, six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; or

(c) R⁸ is selected from hydroxy; mercapto; mono- or di- straight or branched (C₁-C₆)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl and 1-methyl-1-ethylpropyl amino; halo(C₁-C₃)alkyl; acetyl; propionyl; chloroacetyl; trifluoroacetyl; (C₆-C₁₀)aroyl selected from benzoyl and naphthoyl; halo substituted (C₆-C₁₀)aroyl (e.g., pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl); (C₁-C₄)alkylbenzoyl (e.g., 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl); (C₃-C₆)cycloalkylcarbonyl; and (heterocycle)carbonyl, wherein the heterocycle moiety is selected from Q¹, Q², Q³, six membered aromatic rings containing one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se

and an adjacent appended O heteroatom, wherein Q^1 , Q^2 and Q^3 are defined as above;
or

(d) R^8 is selected from (C_1-C_4) alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl and straight or branched butoxycarbonyl; and

R^5 and R^6 are independently selected from hydrogen; straight or branched (C_1-C_3) alkyl selected from methyl, ethyl, n-propyl and 1-methylethyl; (C_6-C_{10}) aryl selected from phenyl, α -naphthyl and β -naphthyl; (C_7-C_9) aralkyl (e.g., benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl); heterocycles selected from the group consisting of Q^1 , Q^2 , Q^3 , six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom; $-(CH_2)_kCOOR^7$ where k is 0-4 and R^7 is selected from hydrogen and straight or branched (C_1-C_3) alkyl selected from methyl, ethyl, n-propyl and 1-methylethyl; and (C_6-C_{10}) aryl selected from phenyl, α -naphthyl and β -naphthyl, wherein Q^1 , Q^2 and Q^3 are defined as above;

or R^5 and R^6 , taken together, are $-(CH_2)_2W(CH_2)_2-$, wherein W is selected from $(CH_2)_q$ wherein q is 0-1, -NH, -N(C_1-C_3)alkyl (straight or branched), -N(C_1-C_4)alkoxy, oxygen, sulfur and substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine and piperidine;

with the proviso that: (a) R^5 and R^6 cannot both be hydrogen.

The compounds of formula I that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of those compounds of formula I that are basic in nature are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzene-sulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

-10-

The compounds of formula I that are acidic in nature are capable of forming a wide variety of base salts. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds.

- 5 Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic
10 amines.

This invention also relates to the pharmaceutically acceptable acid addition and base salts of compounds of the formula I.

A preferred embodiment of this invention relates to compounds of the formula I wherein R^2 is $(C_1-C_6)alkyl-(C=O)-$, phenyl- $(C=O)-$ or phenylmethyl- $(C=O)-$.

- 15 Another preferred embodiment of the invention relates to compounds of the formula I wherein R^3 is $-(C=O)-CH_2-N(CH_3)_2$.

Another preferred embodiment of this invention relates to compounds of the formula I wherein R^3 is $-(C=O)-CH_2-N(CH_3)_2$ and R^1 is hydrogen.

- Examples of specific embodiments of this invention are the following
20 compounds and their pharmaceutically acceptable salts:

- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-oxy-tetracycline;
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-formyloxy-tetracycline;
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-acetoxy-tetracycline;
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-propionyloxy-tetracycline;
- 25 9-dimethylaminoacetyl-amino-6 α -deoxy-5-phenylcarbonyloxy-tetracycline;
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-benzylcarbonyloxy-tetracycline;
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-aminocarbonyloxy-tetracycline;
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-dimethylaminoacetoxo-tetracycline;
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-dimethylaminocarbonyloxy-tetracycline;
- 30 9-dimethylaminoacetyl-amino-6 α -deoxy-5-cyclopentylcarbonyloxy-tetracycline;
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-cyclohexylcarbonyloxy-tetracycline; and
- 9-dimethylaminoacetyl-amino-6 α -deoxy-5-pyridinocarbonyloxy-tetracycline.

-11-

Other embodiments of this invention include compounds of the formula I, and their pharmaceutically acceptable salts, wherein R^3 is selected from the group consisting of formyl, acetyl, methoxyacetyl, acetyloxyacetyl, benzoyl, 4-methoxybenzoyl, 2-methylbenzoyl, 2-fluorobenzoyl, pentafluorobenzoyl, 3-trifluoromethylbenzoyl, 2-furanylcarbonyl, 2-thienylcarbonyl, 4-aminobenzoyl, aminocarbonyl, phenylsulfonyl, 4-chlorophenylsulfonyl, 3-nitrophenylsulfonyl, 2-thienylsulfonyl, 3-nitrophenylsulfonyl, 2-thienylsulfonyl, methanesulfonyl, phenylmethoxyacetyl, hydroxyacetyl, methylaminoacetyl, dimethylaminoacetyl, 4-bromo-1-oxobutyl, (4-dimethylamino)benzoyl, aminoacetyl, ethylsulfonyl, chloroacetyl, bromoacetyl, 2-bromo-1-oxopropyl, cyclopropylaminoacetyl, (2-methylpropyl)aminoacetyl, (butylmethyl)aminoacetyl and (phenylmethyl)aminoacetyl.

Other embodiments of this invention include:

- (a) compounds of the formula I wherein R^2 is other than hydrogen;
- (b) compounds of the formula I wherein R^2 is other than hydrogen and R^3 is $R^8(CH_2)_mCO-$;
- (c) compounds of the formula I wherein R^3 is $R^8(CH_2)_mSO_2-$;
- (d) compounds of the formula I wherein R^2 is other than hydrogen and R^3 is $-(C=O)-CH_2-N(CH_3)_2$;
- (e) compounds of the formula I wherein R^1 is hydrogen;
- (f) compounds of the formula I wherein R^1 is hydrogen and R^2 is other than hydrogen;
- (g) compounds of the formula I wherein R^3 is $R^8(CH_2)_mCO-$;
- (h) compounds of the formula I wherein R^3 is $R^8(CH_2)_mCO-$ and R^8 is other than amino or substituted amino;
- (i) compounds of the formula I wherein R^2 is other than hydrogen, R^3 is $R^8(CH_2)_mCO-$, m is zero or one and R^8 is amino or substituted amino;
- (j) compounds of the formula I wherein R^2 is hydrogen, R^3 is $R^8(CH_2)_mCO-$, m is zero or one and R^8 is other than amino or substituted amino; and
- (k) compounds of the formula I wherein R^2 is hydrogen, R^3 is $R^8(CH_2)_mCO-$, m is zero or one and R^8 is other than (C_1-C_6) alkylamino or $di-(C_1-C_6)$ alkylamino.

Examples of possible Q^1 groups, as defined above for formula I, are the following: pyrrolyl, N-methylindolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolyl, tetrahydrofuranyl, furanyl, tetrahydrothienyl, thienyl, benzothienyl and selenazolyl.

-12-

Examples if possible Q² groups, as defined above for formula I, are the following: imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl and pyridylimidazolyl.

Examples of possible Q³ groups, as defined above for formula I, are
5 γ -butyrolactam, γ -butyrolactone, imidazolidinone and N-aminoimidazolidinone.

Examples of "a six membered saturated ring containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O atom", as used above in the definition of R⁴, are the following: 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl,
10 2-dioxomorpholino and 2-dioxothiomorpholino.

Examples of "a six membered aromatic ring containing from one to three heteroatoms independently selected from N, O, S and Se", as used above in the definition of R⁴, are the following: pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl and (C₁-C₃)alkylthiopyridazenyl.

15 The term "halo", as used herein, refers to chloro, bromo, fluoro and iodo.

The compounds of formula I have chiral centers and therefore exist in different and enantiomeric and diastereomeric forms. This invention relates to all optical isomers and all stereoisomers of compounds of the formula I, and mixtures thereof.

Formula I above also includes compounds identical to those depicted but for
20 the fact that one or more hydrogens or carbon atoms are replaced by isotopes thereof. Such compounds are useful as research and diagnostic tools in metabolism pharmacokinetics studies and in binding assays.

This invention also relates to a pharmaceutical composition for treating or preventing a condition caused by a bacterial infection in a mammal, including a human,
25 comprising an amount of a compound of the formula I, or pharmaceutically acceptable salt thereof, that is effective in treating or preventing such condition, and a pharmaceutical acceptable carrier.

The present invention also relates to a method of treating or preventing a condition caused by a bacterial infection in a mammal, including a human, comprising
30 administering to said mammal an amount of a compound of the formula I, or pharmaceutically acceptable salt thereof, that is effective in treating or preventing such condition.

-13-



The present invention also relates to a pharmaceutical composition for treating or preventing a condition caused by a bacterial infection in a mammal, including a human, comprising an anti-bacterial effective amount of a compound of the formula I, or a pharmaceutical acceptable salt thereof, and a pharmaceutically acceptable carrier.

- 5 The present invention also relates to a method of treating or preventing a condition caused by a bacterial infection in a mammal, including a human, comprising an administering to said mammal an anti-bacterial effective amount of a compound of the formula I, or pharmaceutically acceptable salt thereof.

Detailed Description of the Invention

- 10 Compounds of the formula I may be prepared as depicted in schemes 1-3 and described below. In the reaction schemes and discussion that follows, R¹, R², R³, R⁴, R⁵ and R⁶, unless otherwise indicated, are defined as above.


Scheme 1




6

10

Scheme 2



Scheme 3



-17-

5 Referring to scheme 1, doxycycline (α -6-deoxy-5-oxytetracycline, structure II) is converted into the corresponding intermediate of formula III, wherein R is $R^1(CH_2)_n$, by reacting it with a compound of the formula $RCOOH$, wherein R is defined as above, in methanesulfonic acid. This reaction is generally conducted at a temperature from about 0°C to about 100°C, preferably from about 20°C to about 50°C.

10 Scheme 2 illustrates the conversion compounds of the formula III and doxycycline, which are combined to form generic formula IV, into the corresponding compounds of the formula I wherein R^1 is hydrogen. Referring to scheme 2, compounds of the formula IV are first nitrated at position "9" by reaction with an alkali metal or alkaline earth metal nitrate in a strong acid (e.g., sulfuric, hydrofluoric or
15 methanesulfonic acid). Suitable temperatures for this reaction range from about 0°C to about 25°C, with about 0°C being preferred.

The above nitration reaction yields the corresponding compounds of the formula V. Reduction of the nitro group at position "9" of these compounds yields the corresponding amino derivatives of the formula VI. The reduction is usually
20 accomplished by hydrogenation in the presence of a metal containing catalyst. Suitable hydrogenation catalysts include palladium, platinum, nickel, platinum oxide and rhodium. The reaction temperature may range from about 10°C to about 50°C, with about 25°C being preferred. The hydrogenation is generally carried out at a pressure from about 1 to about 4 atmospheres, preferably from about 1.5 to 3
25 atmospheres, in a suitable inert solvent such as a lower alcohol or acetic acid.

The resulting compounds of the formula VI can be converted into the corresponding compounds of the formula I wherein R^1 is hydrogen (hereinafter referred to as compounds of the formula IA) by reacting them with a compound of the formula R^3X , wherein X is an appropriate leaving group (e.g., chloro, bromo, iodo, mesylate or
30 tosylate) in the presence of a base. Suitable bases include alkali metal and alkaline earth metal carbonates. This reaction is generally conducted in a polar aprotic solvent such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), acetonitrile or dimethylformamide (DMF), preferably DMPU, at a temperature from about 0°C to about 80°C, preferably at about room temperature.

35 Compounds of the formula IA can be converted into the corresponding compounds of the formula I wherein R^1 is $CH_2NR^5R^6$ (hereinafter referred to as compounds of the formula IB) by reacting them with a compound of the formula

NHR⁵R⁸ and formaldehyde. This reaction is typically carried out in a polar solvent such as dimethylformamide (DMF) or a lower alcohol, preferably methoxyethanol, at a temperature from about 0°C to about 100°C, preferably at about 55°C.

The compounds of formula I that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of those compounds of formula I that are basic in nature are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. Although such salts must be pharmaceutically acceptable for administration to mammals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.

The compounds of formula I that are acidic in nature are capable of forming a wide variety of base salts. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines. The pharmaceutically acceptable base addition salts of compounds of the

-19-

formulae I that are acidic in nature may be formed with pharmaceutically acceptable cations by conventional methods. Thus, these salts may be readily prepared by treating the compound of formula I with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, a lower alkyl alcohol solution of the compound of formula I may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated to dryness.

The preparation of other compounds of the formula I not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

In each of the reactions discussed or illustrated in schemes 1 to 3 above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e. about 1 atmosphere, is preferred as a matter of convenience.

The novel compounds of the formula I and the pharmaceutically acceptable salts thereof are useful as antibiotics in mammals, including humans. They are active against a wide range of gram-positive and gram-negative bacterial strains, including organisms that are resistant to tetracycline antibiotics. The antibiotic activity of the compounds of formula I and their pharmaceutically acceptable salts may be determined using the in vitro standard broth dilution method described by Waitz, J. A., National Commission for Clinical Laboratory Standards Document M7-A2, vol. 10, no. 8, pp. 13-20, 2nd edition, Villanova, Pa. (1990).

The compounds of the formula I and the pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered in dosages ranging from about 0.1 mg up to about 1 gram per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 20 mg to about 200 mg per day is most desirably employed. Variations may nevertheless occur depending upon the species of mammal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the above range

-20-

may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

The compounds of the invention may be administered alone or in combination
5 with pharmaceutically acceptable carriers or diluents by either of the three routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic agents of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules,
10 lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general,
15 the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and
20 preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this
25 connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene
30 glycol, glycerin and various like combinations thereof.

For parenteral administration, solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH

-21-

greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

The following examples are given by way of illustration and are not to be construed as limitations of this invention, many variations of which are possible.

Example 1

9-Nitro Doxycycline Sulfate

9-Nitro-Doxycycline was prepared according to the known procedure (J. Med. and Pharm. Chem., 5,538 (1962)). Thus Doxycycline (889 mg, 2 mmol) was dissolved in concentrated sulfuric acid (25 ml) at 0 °C. To it was added solid potassium nitrate (404 mg, 4 mmol). The resulting mixture stirred at 0°C for 20 minutes before it was poured into 100 g of ice. The mixture stirred until all ice chips have melted. Extraction with butanol (4x20 ml portions), washing of butanol with water (2x10 ml), concentration to a small volume to give 9-nitro-doxycycline sulfate as a yellow solid.

Example 2

9-Amino Doxycycline Dihydrochloride

Product of example 1 was dissolved in methanol (1g/100ml) and concentrated hydrochloric acid (1 g/2.3 ml). To it was added platinum oxide catalyst (10% by weight). The mixture was treated with hydrogen at 23°C and 45 psi pressure for 2 hours. Filtration through Celite and concentration gave 9-amino doxycycline dihydrochloride as a yellow solid.

Example 3

9-N,N-dimethylglycylamido-Doxycycline Dihydrochloride

9-Amino doxycycline dihydrochloride (490 mg, 0.92 mmol) was suspended into 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU, 9 ml) and acetonitrile (3 ml). To it was added solid sodium carbonate (488 mg, 5 equiv). After stirring at room temperature for 15 minutes, solid N,N-dimethylglycyl chloride hydrochlorid salt (218

-22-

mg, 1.5 equiv) was added in one portion. The resulting mixture stirred at room temperature for 45 minutes. The insoluble materials were filtered off through filter paper and the filtrate was added dropwise into a solution of methylene chloride (300 ml), ether (150 ml) and 2M hydrochloric acid (HCl) in methanol (8 ml). The resulting yellow solid
5 was collected by filtration and washed with methylene chloride. The crude product thus obtained was dissolved in 0.1 M HCl in methanol (10 ml) and to it was added activated carbon. After stirring for 10 minutes, the mixture was filtered and the filtrate was concentrated in vacuo to dryness. The solid product was dissolved in methanol (5 ml) and the solution was added dropwise into methylene chloride (400 ml). The resulting
10 precipitate was collected by filtration and washed with methylene chloride. The product was dried under a stream of nitrogen for 2 hours and finally under vacuum at 55°C for 24 hours to give 370 mg of the product (65%). ¹H-NMR (250 MHz, DMSO-d₆): 8.10 (d, 1H), 6.95 (d, 1H), 6.00 (d, 1H), 4.59 (s, 1H), 4.20 (s, 2H), 2.86 (s, 3H), 2.79 (s, 3H), 1.50 (d, 3H). FAB-MS: 545 (M+H⁺).

15

Example 4


5-Acyloxy Doxycyclines

Acylation of Doxycycline at 5-position was carried out following the known procedure (II. Farmoc., 29, 902 (1974)). Thus doxycycline (1g) was dissolved in methanesulfonic acid (5 ml) (or hydrofluoric acid) and treated with carboxylic acid (1g)
20 between 23 and 55°C. After the reaction was complete, the mixture was poured into cold ether. The precipitate was collected by filtration and washed with ether to give the doxycycline 5-ester.

-23-

CLAIMS

1. A compound of the formula



10

wherein R^1 is hydrogen or $-CH_2NR^5R^6$;

R^2 is hydrogen or $R^4(CH_2)_nCO-$;

n is an integer from 0 to 4;

R^3 is $R^8(CH_2)_mCO-$ or $R^8(CH_2)_mSO_2-$;

15

m is an integer from 0 to 4;

and when n is 0, then either:

- (a) R^4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C_1-C_6) alkylamino, cyclopropylamino, cyclobutylamino, benzylamino and phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) and 4-(1,2,4-triazolyl); straight or branched (C_1-C_4) alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl; (C_3-C_6) cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; substituted (C_3-C_6) cycloalkyl (substitution selected from (C_1-C_3) alkyl, cyano, amino and (C_1-C_3) acyl); (C_6-C_{10}) aryl selected from phenyl, α -naphthyl and β -naphthyl; substituted (C_6-C_{10}) aryl (substitution selected from halo, (C_1-C_4) alkoxy, trihalo (C_1-C_3) alkyl, nitro, amino, cyano, (C_1-C_4) alkoxycarbonyl, (C_1-C_3) alkylamino and carboxy); (C_7-C_9) aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl and phenylpropyl; α -amino- (C_1-C_4) alkyl selected from aminomethyl, α -aminoethyl, α -aminopropyl and α -aminobutyl; carboxy (C_2-C_4) -alkylamino selected from aminoacetic acid, α -aminobutyric acid and α -aminopropionic acid and their optical isomers; (C_7-C_9) aralkylamino; (C_1-C_4) alkoxycarbonylamino substituted (C_1-C_4) alkyl, substitution selected from phenyl and p-hydroxyphenyl; α -hydroxy (C_1-C_3) alkyl
- 20
- 25
- 30

-24-

selected from hydroxymethyl, α -hydroxyethyl, α -hydroxy-1-methylethyl and α -hydroxypropyl; α -mercaptopropyl; and halo-(C₁-C₃)alkyl; or

(b) R⁴ is selected from Q¹, Q² and Q³, wherein Q¹ is a five membered aromatic or saturated ring containing one N, O, S or Se heteroatom optionally having
5 a benzo or pyrido ring fused thereto;

Q² is a five membered aromatic ring containing two heteroatoms independently selected from N, O, S and Se and optionally having a benzo or pyrido ring fused thereto; and

Q³ is a five membered saturated ring containing one or two heteroatoms
10 independently selected from N, O, S and Se and an adjacent appended O heteroatom; or

(c) R⁴ is a six membered aromatic ring containing from one to three heteroatoms independently selected from N, O, S and Se, or a six membered saturated ring containing one or two heteroatoms independently selected from N, O, S and Se
15 and an adjacent appended O heteroatom; or

(d) R⁴ is selected from acetyl, propionyl; chloroacetyl; trifluoroacetyl; (C₃-C₆)cycloalkylcarbonyl; (C₁-C₁₀)aroyl selected from benzoyl and naphthoyl; halo substituted (C₆-C₁₀)aroyl; (C₁-C₄)alkylbenzoyl; and (heterocycle)carbonyl, wherein said heterocycle is selected from the group consisting of Q¹, Q², Q³, six membered aromatic
20 rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; or

(e) R⁴ is selected from (C₁-C₄)alkoxycarbonyl selected from
25 methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl and allyloxycarbonyl; vinyl; and substituted vinyl [substitution selected from (C₁-C₃)alkyl, halo, (C₆-C₁₀)aryl selected from phenyl, α -naphthyl and β -naphthyl, substituted (C₆-C₁₀)aryl (substitution selected from halo, (C₁-C₄)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl, (C₁-C₃)alkylamino and
30 carboxy), halo(C₁-C₃)alkyl, and Q¹, wherein Q¹ is defined as above]; or

(f) R⁴ is selected from (C₁-C₄)alkoxy; C₆-aryloxy selected from phenoxy and substituted phenoxy (substitution selected from halo, (C₁-C₄)alkyl, nitro, cyano, thiol, amino, carboxy and di(C₁-C₃)alkylamino); (C₇-C₁₀)aralkyloxy; vinyloxy and substituted

-25-

vinylloxy (substitution selected from (C₁-C₄)alkyl, cyano, carboxy, and (C₆-C₁₀)aryl selected from phenyl, α -naphthyl and β -naphthyl); R^aR^b amino(C₁-C₄)alkoxy, wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is
 5 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂- wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S; and R^aR^baminoxy, wherein R^aR^b is a straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂- wherein W
 10 is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S;

and when n is 1, 2, 3 or 4, then either:

(a) R⁴ is selected from hydrogen; amino; straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl; (C₃-C₆)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; substituted (C₃-C₆)cycloalkyl group (substitution selected from (C₁-C₃)alkyl, cyano, amino and (C₁-C₃)acyl); (C₆-C₁₀)aryl selected from phenyl, α -naphthyl and β -naphthyl; substituted (C₆-C₁₀)aryl (substitution selected from halo, (C₁-C₄)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl; (C₁-C₃)alkylamino and carboxy); (C₇-C₉)aralkyl; acetyl; propionyl; chloroacetyl; trichloroacetyl; (C₆-C₁₀)aroyl; (C₁-C₄)alkylbenzoyl; (C₃-C₆)cycloalkylcarbonyl; and (heterocycle)carbonyl, wherein the heterocycle moiety is selected from the group consisting of Q¹, Q², Q³, six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated
 20 rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above;
 25 or

(b) R⁴ is selected from (C₁-C₄)alkoxy; C₆-aryloxy selected from phenoxy and substituted phenoxy (substitution selected from halo, (C₁-C₄)alkyl, nitro, cyano, thiol, amino, carboxy and di(C₁-C₃)alkylamino); (C₇-C₁₀)aralkyloxy; (C₁-C₃)alkylthio selected from methylthio, ethylthio, propylthio and allylthio; C₆-arylthio selected from phenylthio and substituted phenylthio (substitution selected from halo, (C₁-C₄)alkyl, nitro, cyano, thiol, amino, carboxy and di(C₁-C₃)alkylamino); C₆-arylsulfonyl selected from
 30

-26-

phenylsulfonyl and substituted phenylsulfonyl (substitution selected from halo, (C₁-C₄)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl, (C₁-C₃)alkylamino and carboxy); and (C₇-C₈)aralkylthio; or

(c) R⁴ is selected from Q¹, Q², Q³, six membered aromatic rings containing
 5 from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; or

(d) R⁴ is selected from hydroxy; mercapto; mono- or di-straight or branched
 10 chain (C₁-C₆)alkylamino selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl and 1-methyl-1-ethylpropyl amino; (C₂-C₅)azacycloalkyl; carboxy(C₂-C₄)alkylamino selected from
 15 aminoacetic acid, α -aminopropionic acid, α -aminobutyric acid and their optical isomers; α -hydroxy(C₁-C₃)alkyl selected from hydroxymethyl, α -hydroxyethyl, α -hydroxy-1-methylethyl and α -hydroxypropyl; halo(C₁-C₃) alkyl; acetyl; propionyl; chloroacetyl; trifluoroacetyl; (C₆-C₁₀)aroyl selected from benzoyl and naphthoyl; halo substituted (C₆-C₁₀)aroyl; (C₁-C₄)alkylbenzoyl; (C₃-C₆)cycloalkylcarbonyl; and (heterocycle)carbonyl,
 20 wherein the heterocycle moiety is selected from Q¹, Q², Q³, six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; or

(e) R⁴ is selected from (C₁-C₄)alkoxycarbonylamino selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino and propoxycarbonylamino; (C₁-C₄)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, and straight or branched butoxycarbonyl; allyloxycarbonyl; R^aR^bamino(C₁-C₄)alkoxy, wherein R^aR^b
 30 is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂- wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S; and

-27-

R^aR^baminoxy, wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W(CH₂)₂- wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S;

and when R³ is R⁸(CH₂)_mCO and m is 0, then R⁸ is independently selected from the same group of substituents that R⁴ is selected from when n is 0;

and when R³ is R⁸(CH₂)_mCO and m is 1, 2, 3 or 4, then R⁸ is independently selected from the same group of substituents that R⁴ is selected from when n is 1, 2,

3 or 4;

and when R³ is R⁸(CH₂)_mSO₂- and n is 0, then either:

(a) R⁸ is selected from amino; monosubstituted amino selected from straight or branched (C₁-C₆)-alkylamino, cyclopylamino, cyclobutylamino, benzylamino and phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) and 4-(1,2,4-triazolyl); straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl; (C₃-C₆)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; substituted (C₃-C₆)cycloalkyl (substitution selected from (C₁-C₃)alkyl, cyano, amino and (C₁-C₃)acyl); (C₆-C₁₀)aryl selected from phenyl, α-naphthyl and β-naphthyl; substituted (C₆-C₁₀)aryl (substitution selected from halo, (C₁-C₄)alkoxy, trihalo(C₁-C₃)alkyl, nitro, amino, cyano, (C₁-C₄)alkoxycarbonyl, (C₁-C₃)alkylamino and carboxy); (C₇-C₉)aralkyl; and halo(C₁-C₃)alkyl; or

(b) R⁸ is a heterocycle group selected from Q¹, Q², Q³, six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q¹, Q² and Q³ are defined as above; R^aR^bamino(C₁-C₄)alkoxy, wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is (CH₂)_p, wherein p is 2-6, or R^aR^b is -(CH₂)₂W-(CH₂)₂-, wherein W is selected from -N(C₁-C₃)alkyl (straight or branched), -NH, -NOB (wherein B is selected from hydrogen and (C₁-C₃)alkyl), O and S; and R^aR^b aminoxy, wherein R^aR^b is straight or branched (C₁-C₄)alkyl selected from methyl, ethyl,

-28-

n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is $(CH_2)_p$, wherein p is 2-6, or R^aR^b is $-(CH_2)_2W(CH_2)_2-$ wherein W is selected from $-N(C_1-C_3)alkyl$ (straight or branched), $-NH$, $-NOB$ (wherein B is selected from hydrogen or $(C_1-C_3)alkyl$), O and S, wherein Q^1 , Q^2 and Q^3 are defined as above;

5 and when R^3 is $R^8(CH_2)_mSO_2-$ and n is 1, 2, 3 or 4, then either:

(a) R^8 is selected from hydrogen; straight or branched $(C_1-C_4)alkyl$ selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl; $(C_1-C_4)carboxyalkyl$; $(C_3-C_6)cycloalkyl$ selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; substituted $(C_3-C_6)cycloalkyl$ (substitution selected from $(C_1-C_3)alkyl$, cyano, amino and $(C_1-C_3)acyl$); $(C_6-C_{10})aryl$ selected from phenyl, α -naphthyl and β -naphthyl; substituted $(C_6-C_{10})aryl$ (substitution selected from halo, $(C_1-C_3)alkoxy$, trihalo $(C_1-C_3)alkyl$, nitro, amino, cyano, $(C_1-C_4)alkoxycarbonyl$, $(C_1-C_3)alkylamino$ and carboxy); $(C_7-C_8)aralkyl$; $(C_1-C_4)alkoxy$; C_6 -aryloxy selected from phenoxy and substituted phenoxy (substitution selected from halo, $(C_1-C_3)alkyl$, nitro, cyano, thiol, amino, carboxy and $di(C_1-C_3)alkylamino$); $(C_7-C_{10})aralkyloxy$; R^aR^b amino $(C_1-C_4)alkoxy$, wherein R^aR^b is straight or branched $(C_1-C_4)alkyl$ selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is $(CH_2)_p$, wherein p is 2-6, or R^aR^b is $-(CH_2)_2W(CH_2)_2-$, wherein W selected from $-N(C_1-C_3)alkyl$ (straight or branched), $-NH$, $-NOB$ (wherein B is selected from hydrogen and $(C_1-C_3)alkyl$), O and S; and R^aR^b aminoxy, wherein R^aR^b is straight or branched $(C_1-C_4)alkyl$ selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, and 2-methylpropyl, or R^aR^b is $(CH_2)_p$, wherein p is 2-6, or R^aR^b is $-(CH_2)_2W(CH_2)_2-$, wherein W is selected from $-N(C_1-C_3)alkyl$ (straight or branched), $-NH$, $-NOB$ (wherein B is selected from hydrogen and $(C_1-C_3)alkyl$), O and S; or

25 (b) R^8 is selected from $(C_1-C_3)alkylthio$ selected from methylthio, ethylthio and n-propylthio; C_6 -arylthio selected from phenylthio and substituted phenylthio (substitution selected from halo, $(C_1-C_3)alkyl$, nitro, cyano, thiol, amino, carboxy and $di(C_1-C_3)alkylamino$); $(C_7-C_8)aralkylthio$; and heterocycle groups selected from the group consisting of Q^1 , Q^2 , Q^3 , six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q^1 , Q^2 and Q^3 are defined as above;

30 or

-29-

(c) R^8 is selected from hydroxy; mercapto; mono- or di- straight or branched (C_1 - C_8)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl and 1-methyl-1-ethylpropyl amino; halo(C_1 - C_3)alkyl; acetyl; propionyl; chloroacetyl; trifluoroacetyl; (C_6 - C_{10})aryl selected from benzoyl and naphthoyl; halo substituted (C_6 - C_{10})aryl; (C_1 - C_4)alkylbenzoyl; (C_3 - C_6)cycloalkylcarbonyl; and (heterocycle)carbonyl, wherein the heterocycle moiety is selected from Q^1 , Q^2 , Q^3 , six membered aromatic rings containing one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom, wherein Q^1 , Q^2 and Q^3 are defined as above; or

(d) R^8 is selected from (C_1 - C_4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl and straight or branched butoxycarbonyl; and

R^5 and R^6 are independently selected from hydrogen; straight or branched (C_1 - C_3)alkyl selected from methyl, ethyl, n-propyl and 1-methylethyl; (C_6 - C_{10})aryl selected from phenyl, α -naphthyl and β -naphthyl; (C_7 - C_9)aralkyl; heterocycles selected from the group consisting of Q^1 , Q^2 , Q^3 , six membered aromatic rings containing from one to three heteroatoms independently selected from N, O, S and Se, and six membered saturated rings containing one or two heteroatoms independently selected from N, O, S and Se and an adjacent appended O heteroatom; $-(CH_2)_kCOOR^7$ where k is 0-4 and R^7 is selected from hydrogen and straight or branched (C_1 - C_3)alkyl selected from methyl, ethyl, n-propyl and 1-methylethyl; and (C_6 - C_{10})aryl selected from phenyl, α -naphthyl and β -naphthyl, wherein Q^1 , Q^2 and Q^3 are defined as above;

or R^5 and R^6 , taken together, are $-(CH_2)_2W(CH_2)_2-$, wherein W is selected from $(CH_2)_q$ wherein q is 0-1, -NH, -N(C_1 - C_3)alkyl (straight or branched), -N(C_1 - C_4)alkoxy, oxygen, sulfur and substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine and piperidine;

with the proviso that: (a) R^5 and R^6 can not both be hydrogen; or a pharmaceutically acceptable salt of such compound.

-30-

2. A compound according to claim 1 wherein R^2 is hydrogen, R^3 is $R^8(CH_2)_mCO-$, m is zero or one and R^8 is other than $(C_1-C_6)alkylamino$ or $di-(C_1-C_6)alkylamino$.
3. A compound according to claim 2 wherein R^8 is other than amino or substituted amino.
4. A compound according to claim 1, wherein R^2 is other than hydrogen.
5. A compound according to claim 4, wherein R^3 is $R^8(CH_2)_mCO-$.
6. A compound according to claim 1, wherein R^3 is $R^8(CH_2)_mSO_2-$.
7. A compound according to claim 4, wherein R^2 is $(C_1-C_6)alkyl-(C=O)-$, phenyl- $(C=O)-$ or phenylmethyl- $(C=O)-$.
8. A compound according to claim 5, wherein R^3 is $-(C=O)-CH_2-N(CH_3)_2$.
9. A compound according to claim 1, wherein R^1 is hydrogen and R^2 is hydrogen.
10. A compound according to claim 1, wherein R^3 is selected from the group consisting of formyl, acetyl, methoxyacetyl, acetyloxyacetyl, benzoyl, 4-methoxybenzoyl, 2-methylbenzoyl, 2-fluorobenzoyl, pentafluorobenzoyl, 3-trifluoromethylbenzoyl, 2-furanylcarbonyl, 2-thienylcarbonyl, 4-aminobenzoyl, aminocarbonyl, phenylsulfonyl, 4-chlorophenylsulfonyl, 3-nitrophenylsulfonyl, 2-thienylsulfonyl, 3-nitrophenylsulfonyl, 2-thienylsulfonyl, methanesulfonyl, phenylmethoxyacetyl, hydroxyacetyl, methylaminoacetyl, dimethylaminoacetyl, 4-bromo-1-oxobutyl, (4-dimethylamino)benzoyl, aminoacetyl, ethylsulfonyl, chloroacetyl, bromoacetyl, 2-bromo-1-oxopropyl, cyclopropylaminoacetyl, (2-methylpropyl)aminoacetyl, (butylmethyl)aminoacetyl and (phenylmethyl)aminoacetyl.
11. A pharmaceutical composition for treating or preventing a condition caused by a bacterial infection in a mammal, including a human, comprising an amount of a compound according to claim 1 that is effective in treating or preventing such condition, and a pharmaceutical acceptable carrier.
12. A method of treating or preventing a condition caused by a bacterial infection in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating or preventing such condition.
13. A pharmaceutical composition for treating or preventing a condition caused by a bacterial infection in a mammal, including a human, comprising an anti-

-31-

bacterial effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

14. A method of treating or preventing a condition caused by a bacterial infection in a mammal, including a human, comprising administering to said mammal
- 5 an anti-bacterial effective amount of a compound according to claim 1.

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/IB 95/00026

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D213/79 C07C237/26 A61K31/44 A61K31/65

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,3 338 963 (PETISI J. ET AL.) 29 August 1967 see claim 1	1-3, 9-11,13
P,X	EP,A,0 618 190 (AMERICAN CYANAMID COMPANY) 5 October 1994 see claims 1-12	1,2, 9-11,13
Y	JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, vol. 5,no. 3, May 1962 pages 538-546, PETISI J. ET AL. '6-Deoxytetracyclines. II. Nitrations and subsequent reactions' cited in the application see the whole document	1-11,13
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "&" document member of the same patent family

Date of the actual completion of the international search

28 April 1995

Date of mailing of the international search report

18.05.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Hartrampf, G

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/IB 95/00026

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 85,no. 17, 5 September 1963 pages 2643-2652, STEPHENS C.R. ET AL. '6-Deoxytetracyclines. IV. Preparation, C-6 stereochemistry, and reactions' cited in the application see the whole document ---	1-11,13
Y	CHEMICAL ABSTRACTS, vol. 72, no. 11, 16 March 1970 Columbus, Ohio, US; abstract no. 55095b, BLACKWOOD R.K. 'Water soluble .alpha.-6-deoxy-5-hydroxytetracycline derivatives' page 388; column 1; see abstract & DE,A,19 14 194 (PFIZER, CHAS., AND CO., INC.) 2 October 1969 ---	1-11,13
Y	JOURNAL OF MEDICINAL CHEMISTRY, vol. 36,no. 3, 5 February 1993 pages 370-377, NELSON M.L. ET AL. 'Inhibition of the tetracycline efflux antiport protein be 13-thio-substituted 5-hydroxy-6-deoxytetracyclines' see the whole document ---	1-11,13
Y	EP,A,0 536 515 (AMERICAN CYANAMID COMPANY) 14 April 1993 cited in the application see the whole document ---	1-11,13
Y	JOURNAL OF MEDICINAL CHEMISTRY, vol. 37,no. 1, 7 January 1994 pages 184-188, SUM P.-E. ET AL. 'Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines' see the whole document ---	1-11,13
Y	EP,A,0 582 788 (AMERICAN CYANAMID COMPANY) 16 February 1994 see the whole document -----	1-11,13

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PC1, 1B 95/00026

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12 and 14 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/IB 95/00026

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-3338963	29-08-67	NONE		

EP-A-618190	05-10-94	US-A-	5371076	06-12-94
		CA-A-	2120374	03-10-94

EP-A-536515	14-04-93	AU-B-	654049	20-10-94
		AU-A-	2618392	08-04-93
		CA-A-	2079692	05-04-93
		JP-A-	5255219	05-10-93
		ZA-A-	9207607	13-04-93

EP-A-582788	16-02-94	US-A-	5328902	12-07-94
		AU-B-	4461293	17-02-94
		CA-A-	2103836	14-02-94
		CN-A-	1083805	16-03-94
		CZ-A-	9301599	16-03-94
		FI-A-	933565	14-02-94
		HU-A-	64943	28-03-94
		JP-A-	6206855	26-07-94
		NO-A-	932869	14-02-94
		PL-A-	300063	21-02-94
		US-A-	5401729	28-03-95
		US-A-	5380888	10-01-95

Form PCT/ISA/210 (patent family annex) (July 1992)